文献速递胃肠外科围术期管理与 ERAS

减重手术与6年后抗糖尿病治疗持续、终止或起始率的相关性

Association Between Bariatric Surgery and Rates of Continuation, Discontinuation, or Initiation of Antidiabetes Treatment 6 Years Later.
PubMed 文献 · JAMA Surg · 2018-01-01

这项法国全国性观察性队列研究匹配了2009年接受初次减重手术的患者与未手术的肥胖对照,发现术后6年抗糖尿病治疗终止率显著高于对照(-49.9% vs -9.0%),且起始率显著更低(1.4% vs 12.0%)。胃旁路术与治疗终止的关联最强(OR 16.7),并对起始治疗显示保护作用(OR 0.06)。

要点

  • 减重术后6年抗糖尿病治疗终止率显著高于肥胖对照(-49.9% vs -9.0%)。
  • 胃旁路术与治疗终止关联最强(OR 16.7),袖状胃切除术次之(OR 7.30)。
  • 基线未治疗者术后6年起始抗糖尿病治疗率显著低于对照(1.4% vs 12.0%)。

核心结论

  • 减重手术与术后6年抗糖尿病治疗终止率显著高于基线及未手术肥胖对照相关。
  • 减重手术与基线未治疗者6年抗糖尿病治疗起始率显著低于对照相关。

研究设计与样本

  • 全国性观察性人口队列研究,提取法国国家医疗保险数据库2008年1月1日至2015年12月31日报销数据。
  • 2009年接受初次减重手术的患者按年龄、性别、BMI分类和抗糖尿病治疗与2009年因肥胖住院且2005-2015年未手术的对照匹配。
  • 共15 650例手术患者,平均年龄38.9岁(SD 11.2),84.6%女性,1633例基线接受抗糖尿病治疗;术式包括可调节胃束带术48.5%、胃旁路术27.7%、袖状胃切除术22.0%。

主要发现

  • 基线接受抗糖尿病治疗者中,术后6年治疗终止率手术组为-49.9%,对照组为-9.0%(P < .001)。
  • 多变量分析中,与无减重手术相比,治疗终止的预测因素包括胃旁路术(OR 16.7;95%CI 13.0-21.4)、袖状胃切除术(OR 7.30;95%CI 5.50-9.50)和可调节胃束带术(OR 4.30;95%CI 3.30-5.60)。
  • 胰岛素使用(OR 0.17;95%CI 0.13-0.22)、无胰岛素的双联治疗(OR 0.38;95%CI 0.32-0.45)相对于单药治疗、降脂治疗(OR 0.76;95%CI 0.63-0.91)、抗抑郁治疗(OR 0.67;95%CI 0.55-0.81)及年龄每增加1岁(OR 0.96;95%CI 0.95-0.97)与治疗终止相关。
  • 基线未接受抗糖尿病治疗者中,术后6年治疗起始率手术组为1.4%,对照组为12.0%(P < .001)。
  • 多变量分析中,与对照相比,胃旁路术(OR 0.06;95%CI 0.04-0.09)、袖状胃切除术(OR 0.08;95%CI 0.06-0.11)和可调节胃束带术(OR 0.16;95%CI 0.14-0.20)为治疗起始的保护因素;BMI分类≥50.0 vs 30.0-39.9(OR 2.04;95%CI 1.68-2.47)、40.0-49.9 vs 30.0-39.9(OR 1.68;95%CI 1.49-1.90)、降压治疗(OR 1.49;95%CI 1.33-1.67)、低收入(OR 1.43;95%CI 1.26-1.62)及年龄每增加1岁(OR 1.04;95%CI 1.03-1.05)为风险因素。

临床怎么用

  • 对于肥胖合并2型糖尿病患者,减重手术(尤其是胃旁路术)与更高的6年抗糖尿病治疗终止率相关,可考虑作为糖尿病综合管理策略。
  • 术后6年抗糖尿病治疗起始率低,提示减重手术可能有助于预防高危肥胖患者糖尿病的发生。
  • 基线使用胰岛素、双联治疗、降脂药或抗抑郁药的患者治疗终止可能性较低,术后需个体化评估和随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Few large-scale long-term prospective cohort studies have assessed changes in antidiabetes treatment after bariatric surgery. OBJECTIVE: To describe the association between bariatric surgery and rates of continuation, discontinuation, or initiation of antidiabetes treatment 6 years after bariatric surgery compared with a matched control obese group. DESIGN, SETTING, AND PARTICIPANTS: This nationwide observational population-based cohort study extracted health care reimbursement data from the French national health insurance database from January 1, 2008, to December 31, 2015. All patients undergoing primary bariatric surgery in France between January 1 and December 31, 2009, were matched on age, sex, body mass index category, and antidiabetes treatment with control patients hospitalized for obesity in 2009 with no bariatric surgery between 2005 and 2015. EXPOSURES: Bariatric surgery, including adjustable gastric banding (AGB), gastric bypass (GBP), and sleeve gastrectomy (SG). MAIN OUTCOME AND MEASURE: Reimbursement for antidiabetes drugs. Mixed-effects logistic regression models estimated factors of discontinuation or initiation of antidiabetes treatment over a period of 6 years. RESULTS: In 2009, a total of 15 650 patients (mean [SD] age, 38.9 [11.2] years; 84.6% female; 1633 receiving antidiabetes treatment) underwent primary bariatric surgery, with 48.5% undergoing AGB, 27.7% undergoing GBP, and 22.0% undergoing SG. Among patients receiving antidiabetes treatment at baseline, the antidiabetes treatment discontinuation rate was higher 6 years after bariatric surgery than in controls (-49.9% vs -9.0%, P < .001). In multivariable analysis, the main predictive factors for discontinuation were the following: GBP (odds ratio [OR], 16.7; 95% CI, 13.0-21.4), SG (OR, 7.30; 95% CI, 5.50-9.50), and AGB (OR, 4.30; 95% CI, 3.30-5.60) compared with no bariatric surgery, as well as insulin use (OR, 0.17; 95% CI, 0.13-0.22), dual therapy without insulin (OR, 0.38; 95% CI, 0.32-0.45) vs monotherapy, lipid-lowering treatment (OR, 0.76; 95% CI, 0.63-0.91), antidepressant treatment (OR, 0.67; 95% CI, 0.55-0.81), and age (OR, 0.96; 95% CI, 0.95-0.97) per year. For patients without antidiabetes treatment at baseline, the 6-year antidiabetes treatment initiation rate was much lower after bariatric surgery than in controls (1.4% vs 12.0%, P < .001). In multivariable analysis, protective factors were GBP (OR, 0.06; 95% CI, 0.04-0.09), SG (OR, 0.08; 95% CI, 0.06-0.11), and AGB (OR, 0.16; 95% CI, 0.14-0.20) vs controls, and risk factors were as follows: body mass index category (OR, 2.04; 95% CI, 1.68-2.47 for ≥50.0 vs 30.0-39.9 and OR, 1.68; 95% CI, 1.49-1.90 for 40.0-49.9 vs 30.0-39.9), antihypertensive treatment (OR, 1.49; 95% CI, 1.33-1.67), low income (OR, 1.43; 95 % CI, 1.26-1.62), and age (OR, 1.04; 95 % CI, 1.03-1.05) per year. CONCLUSIONS AND RELEVANCE: Bariatric surgery was associated with a significantly higher 6-year postoperative antidiabetes treatment discontinuation rate compared with baseline and with an obese control group without bariatric surgery.

来源:JAMA Surg,查看原文。版权归原作者所有。

引用

  1. Thereaux J, Lesuffleur T, Czernichow S, et al. Association Between Bariatric Surgery and Rates of Continuation, Discontinuation, or Initiation of Antidiabetes Treatment 6 Years Later. JAMA Surg. 2018. PMID: 29450469. doi:10.1001/jamasurg.2017.6163

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。